Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPA: Palbociclib + PI3K Inhibitors (Taselisib/Pictilisib) in Advanced Cancer
NCT02389842Phase 1Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of taselisib / pictilisib and pictilisib in solid tumor (advanced stage) and breast cancer, sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Recommended dose for Phase II at 24 months, Safety and Toxicity Profile at 24 months and 1 more. Started Mar 2015; status: completed.
02
Drugs
taselisib / pictilisibpictilisib
03
Conditions
solid tumor (advanced stage)breast cancer
Beyond the preview
Go deeper on NCT02389842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389842.